摘要
目的基于免疫细胞浸润的免疫评分模型探讨程序性死亡受体1(PD-1)抑制剂治疗晚期肝细胞癌(HCC)后生存获益。方法下载120例晚期HCC组织和6例正常组织基因表达数据及相关临床参数,通过Cibersort软件计算肿瘤组织中22种免疫细胞的浸润情况,通过LASSO分析筛选关键预测因子,将符合条件的免疫细胞构建预后生存评分模型。将晚期HCC患者分为高风险组(n=83)和低风险组(n=37),并通过Kaplan-Meier生存曲线进行验证。基于风险模型建立列线图模型预测晚期HCC患者的死亡概率,并对模型的区分度、准确度和可靠性进行评价。结果与正常组织相比,晚期HCC肿瘤组织中活化的树突细胞、静息的树突细胞、M1巨噬细胞和M0巨噬细胞含量较高;静息肥大细胞、活化的肥大细胞、中性粒细胞和M2巨噬细胞含量较低。根据6个浸润免疫细胞,计算样本的风险评分,随着风险评分的升高,高风险组晚期HCC患者增多,死亡人数增多。生存曲线结果显示高风险患者总生存时间显著低于低风险组(Log-Rankχ2=4.327,P<0.001)。预后列线图模型总分303分,对应死亡风险为71%。模型验证结果显示列线图模型具有较高的区分度、准确度和可靠性。结论PD-1抑制剂治疗有可能使晚期HCC患者生存获益,且基于免疫细浸润的免疫评分模型对患者生存获益具有一定的预测价值。
Objective Study on survival benefit of PD-1 inhibitor after treatment of advanced hepatocellular carcinoma based on immune scoring model of immune cell infiltration.Methods Download the gene expression data of 120 cases of advanced hepatocellular carcinoma tissues and 6 cases of normal liver tissues and relevant clinial parameters of patients.The infiltration of 22 kinds of immune cells in tumor tissue was calculated by Cibersort software.Key predictors were screened through LASSO analysis.The eligible immune cells were used to construct the prognostic survival score model.The patients with advanced hepatocellular carcinoma were divided into high risk group(n=83)and low risk group(n=37),and verified by Kaplan-Meier survival curve.Based on the risk model,a nomograph model was established to predict the death probability of patients with advanced hepatocellular carcinoma.The discrimination,accuracy and reliability of the model are evaluated.Results Compared with normal tissues,the contents of activated dendritic cells,resting dendritic cells,M1 macrophages and M0 macrophages in tumor tissues of advanced hepatocellular carcinoma were higher;The content of resting mast cells,activated mast cells,neutrophils and M2 macrophages were low.According to 6 infiltrating immune cells,the risk score of the sample was calculated.With the increase of risk score,the number of patients with advanced hepatocellular carcinoma in the high-risk group increased and the number of deaths increased.The survival curve results showed that the total survival time of high-risk patients was significantly lower than that of low-risk patients(Log-Rankχ2=4.327,P<0.001).The total score of the prognostic nomogram model was 303,and the corresponding risk of death was 71%.The model validation results show that the nomograph model has high discrimination,accuracy and reliability.Conclusion PD-1 inhibitor treatment may benefit the survival of patients with advanced hepatocellular carcinoma,and the immune score model based on immune fine infiltration h
作者
姚荣飞
钟丁亮
黄佰权
YAO Rongfei;ZHONG Dingliang;HUANG Baiquan(Department of Pharmacy,Pearl River Hospital,Southern Medical University,Guangzhou 510000,China)
出处
《西部医学》
2024年第7期963-967,973,共6页
Medical Journal of West China
